Pulmonary Function Testing (PFT) is a vital tool in diagnosing and managing respiratory diseases. However, interpreting the results can be complex for healthcare professionals. This guide aims to simplify the process.
Spirometry, the most common PFT, measures the amount (volume) and speed (flow) of air that can be inhaled and exhaled. Key values include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), and their ratio (FEV1/FVC). Abnormalities in these values can indicate obstructive or restrictive lung diseases.
Obstructive disorders, such as COPD and asthma, are characterized by reduced airflow. This is reflected in a decreased FEV1/FVC ratio. On the other hand, restrictive disorders like pulmonary fibrosis present with reduced lung volumes (FVC), but normal or increased FEV1/FVC ratio.
Gas exchange tests, such as the diffusion capacity for carbon monoxide (DLCO), provide insight into the lung’s ability to transfer gases between the alveoli and the bloodstream. Reduced DLCO can indicate diseases like emphysema or pulmonary hypertension.
Interpretation of PFT results should always be integrated with the patient's symptoms, physical examination, and other diagnostic tests. For instance, a reduced FEV1/FVC ratio accompanied by wheezing and episodic breathlessness may suggest asthma.
Interpreting PFT results is a nuanced process that requires a comprehensive understanding of respiratory physiology and clinical context. By understanding spirometry and gas exchange testing, and recognizing obstructive and restrictive patterns, healthcare professionals can more accurately diagnose and manage respiratory diseases.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation